Company: MBIO
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001104659-25-032236
Chunk: 18

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-04
Form: POS AM
Chunk 18
---
 Agreement, we agreed to issue and sell the June 2024 Warrants at an offering price of $20.50 per warrant to purchase one
share of common stock. The June 2024 Warrants have an exercise price of $20.50 per share (subject to adjustment as set forth in the
June 2024 Warrants), were exercisable immediately upon issuance and will expire five and one-half (5.5) years from the date
on which the June 2024 Warrants become exercisable. The June 2024 Warrants contain standard anti-dilution adjustments to the
exercise price including for share splits, share dividend, rights offerings and pro rata distributions. This offering closed on June 21,
2024, concurrently with a registered direct offering with the same institutional accredited investor that was registered under the Securities
Act. The gross proceeds to us from the private placement, before deducting placement agent fees and other estimated offering expenses
payable by us, were approximately $2.51 million. Wainwright acted as the placement agent in connection with the private placement pursuant
to an engagement agreement, between us and Wainwright. Wainwright was paid a cash fee equal to 7.0% of the gross proceeds received us
in the offerings, a management fee equal to 1.0% of the gross proceeds of the offerings, $75,000 for non-accountable expenses and a clearing
fee of $15,950. In addition, under the terms of the engagement letter with Wainwright, we issued to Wainwright (or its designees) warrants
to purchase up to 7,355 shares of our common stock The warrants issued to Wainwright have substantially the same terms as the June 2024
Warrants, except that the Wainwright warrants will expire five (5) years from the commencement of the sales of the offerings and
have an exercise price of $25.625 per share (subject to customary adjustment as set forth in the Wainwright warrants). The June 2024
Warrants were offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities
Act. The investor also represented that it qualified as an “accredited investor” within the meaning of Rule 501 of Regulation
D.

October 2024 Private Placement

On October 24, 2024, we entered into an inducement
offer letter agreement (the “Inducement Letter”) with an